Bausch Health Companies Inc. buy Quitte
Zusammenfassung
Diese Einschätzung wurde am 07.06.16 mit einem Endkurs von 20,58 € beendet. Mit einer Rendite von -22,73 % entwickelte sich die Einschätzung BUY nicht nach Plan. Quitte hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Bausch Health Companies Inc. | 4,09 % | 4,09 % | -32,07 % | -78,31 % |
iShares Core DAX® | 2,76 % | 0,82 % | 17,07 % | 13,81 % |
iShares Nasdaq 100 | 2,59 % | -1,33 % | 31,63 % | 38,85 % |
iShares Nikkei 225® | 3,11 % | 0,17 % | 17,18 % | 9,89 % |
iShares S&P 500 | 1,86 % | -0,53 % | 26,70 % | 37,48 % |
Kommentare von Quitte zu dieser Einschätzung
In der Diskussion Bausch Health Companies Inc. diskutieren
neue Besen kehren gut
nach wie vor aber mit großem Risiko behaftet!
Valeant Pharma Initiates Search For New CEO; Plans Restatement - Quick Facts
(RTTNews.com) - Valeant Pharmaceuticals International, Inc. (VRX, VRX.TO) announced its board has initiated a search to identify a candidate to succeed Michael Pearson as CEO. The company also announced William Ackman, CEO of Pershing Square Capital Management, L.P., will join its board, effective immediately. Katharine Stevenson voluntarily resigned from the Board to create a vacancy for Ackman's appointment.
Valeant Pharma said it has identified misstatements that would reduce previously reported fiscal year 2014 revenue by approximately $58 million, net income attributable to Valeant by approximately $33 million, and earnings per share by $0.09. The company has identified misstatements in the first quarter of 2015, consisting primarily of the reversing effect on earnings of the 2014 misstatements, which would reduce revenue by approximately $21 million, increase net income attributable to Valeant by approximately $24 million and increase earnings per share by $0.07.
The company said it is in the process of restating the affected financial statements and the restated financial statements will be included in the company's Annual Report on Form 10-K for the year ended December 31, 2015, which the company intends to file with the SEC and the Canadian Securities Regulators on or before April 29, 2016.
Beendete Einschätzungen von Quitte zu Bausch Health Companies Inc.
Bausch Health Companies Inc.
14.03.18
14.09.18
14.09.18
Bausch Health Companies Inc.
06.07.16
18.08.16
18.08.16